Download PDF
Semin Thromb Hemost 2007; 33(8): 798-809
DOI: 10.1055/s-2007-1000372
© Thieme Medical Publishers

Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review

Ashraf Mina1 , 2 , Emmanuel J. Favaloro1 , Jerry Koutts1
  • 1Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia
  • 2Australian Institute of Medical Scientists for New South Wales, Sydney, Australia
Further Information

Publication History

Publication Date:
04 January 2008 (online)

    Permissions and Reprints

ABSTRACT

We review the association between disorders of endocrine function and hemostasis. The content of more than 570 review articles were appraised to provide the core of 81 key articles referenced in this chapter. The search method used MEDLINE and EMBASE electronic databases and the key words endocrine dysfunction, diabetes, Graves' disease, hypothyroidism, hyperthyroidism, thyrotoxicosis, von Willebrand disease, von Willebrand factor, bleeding disorders, platelets dysfunction, hemostasis dysfunction, and review. Abnormalities of hemostasis, platelets, and endothelium and the presence of microparticles, abnormal expression of adhesion molecules, and elevated von Willebrand factor are all associated with cardiovascular disease and are also features of various endocrine disorders, including diabetes and its complications, insulin resistance, polycystic ovary syndrome, and various thyroid disorders. Related causes and associated factors, including obesity, alcohol, hyperlipidemia, omega fatty acids, vitamin D, serotonin, insulin-like growth factors, angiotensin-converting enzyme, and C-reactive protein, are also discussed in this review.

KEYWORDS

Adhesion molecules - endocrine disorders - endothelium - hemostasis - platelets

REFERENCES

  • 1 Tomoriova E, Tkac I, Takac M. Hypercoagulation states.  Vnitr Lek. 1993;  39 1114-1119
    PubMedGoogle Scholar
  • 2 Schafer A I. The hypercoagulable states.  Ann Intern Med. 1985;  102 814-828
    PubMedGoogle Scholar
  • 3 Palumbo P J. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.  J Diabetes Complications. 1998;  12 110-119
    CrossrefPubMedGoogle Scholar
  • 4 Sowers J R. Diabetes mellitus and cardiovascular disease in women.  Arch Intern Med. 1998;  158 617-621
    CrossrefPubMedGoogle Scholar
  • 5 Clemetson K J. Platelet receptors and their role in diseases.  Clin Chem Lab Med. 2003;  41 253-260
    CrossrefPubMedGoogle Scholar
  • 6 Packham M A, Mustard J F. The role of platelets in the development and complications of atherosclerosis.  Semin Hematol. 1986;  23 8-26
    PubMedGoogle Scholar
  • 7 Nordt T K, Bode C. Endothelium and endogenous fibrinolysis.  Z Kardiol. 2000;  89 219-226
    PubMedGoogle Scholar
  • 8 Becker B F, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis.  Z Kardiol. 2000;  89 160-167
    PubMedGoogle Scholar
  • 9 Sumpio B E, Riley J T, Dardik A. Cells in focus: endothelial cell.  Int J Biochem Cell Biol. 2002;  34 1508-1512
    CrossrefPubMedGoogle Scholar
  • 10 Nabel E G. Biology of the impaired endothelium.  Am J Cardiol. 1991;  68 6C-8C
    CrossrefPubMedGoogle Scholar
  • 11 Berkenboom G. Vascular endothelium: target organ of cardiovascular pathologies.  Ann Cardiol Angeiol (Paris). 1999;  48 643-646
    PubMedGoogle Scholar
  • 12 Mancini M, Rubba P. Ischemic cardiopathy: risk factors and their biological role.  Ital Heart J. 2000;  1(Suppl 2) 17-22
    PubMedGoogle Scholar
  • 13 Simon B C, Noll B, Maisch B. Endothelial dysfunction-assessment of current status and approaches to therapy.  Herz. 1999;  24 62-71
    PubMedGoogle Scholar
  • 14 Willerson J T. Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products.  Tex Heart Inst J. 1995;  22 13-19
    PubMedGoogle Scholar
  • 15 Vallance P, Calver A, Collier J. The vascular endothelium in diabetes and hypertension.  J Hypertens Suppl. 1992;  10 S25-S29
    CrossrefPubMedGoogle Scholar
  • 16 Mehta J L, Nicolini F A, Donnelly W H, Nichols W W. Platelet-leukocyte-endothelial interactions in coronary artery disease.  Am J Cardiol. 1992;  69 8B-13B
    CrossrefPubMedGoogle Scholar
  • 17 Harrison D G, Kurz M A, Quillen J E, Sellke F W, Mugge A. Normal and pathophysiologic considerations of endothelial regulation of vascular tone and their relevance to nitrate therapy.  Am J Cardiol. 1992;  70 11B-17B
    CrossrefPubMedGoogle Scholar
  • 18 Pomilio M, Mohn A, Verrotti A, Chiarelli F. Endothelial dysfunction in children with type 1 diabetes mellitus.  J Pediatr Endocrinol Metab. 2002;  15 343-361
    PubMedGoogle Scholar
  • 19 Horstman L L, Jy W, Jimenez J J, Ahn Y S. Endothelial microparticles as markers of endothelial dysfunction.  Front Biosci. 2004;  9 1118-1135
    CrossrefPubMedGoogle Scholar
  • 20 Krieglstein C F, Granger D N. Adhesion molecules and their role in vascular disease.  Am J Hypertens. 2001;  14 44S-54S
    CrossrefPubMedGoogle Scholar
  • 21 Blann A D. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years.  Thromb Haemost. 2006;  95 49-55
    PubMedGoogle Scholar
  • 22 Blann A D, McCollum C N. von Willebrand factor, endothelial cell damage and atherosclerosis.  Eur J Vasc Surg. 1994;  8 10-15
    CrossrefPubMedGoogle Scholar
  • 23 Blann A. Willebrand factor and the endothelium in vascular disease.  Br J Biomed Sci. 1993;  50 125-134
    PubMedGoogle Scholar
  • 24 Lip G Y, von Blann A. Willebrand factor: a marker of endothelial dysfunction in vascular disorders?.  Cardiovasc Res. 1997;  34 255-265
    CrossrefPubMedGoogle Scholar
  • 25 van Mourik J A, Romani de Wit T. Von Willebrand factor propeptide in vascular disorders.  Thromb Haemost. 2001;  86 164-171
    PubMedGoogle Scholar
  • 26 Nitu-Whalley I C, Lee C A. Acquired von Willebrand syndrome-report of 10 cases and review of the literature.  Haemophilia. 1999;  5 318-326
    CrossrefPubMedGoogle Scholar
  • 27 Rinder M R, Richard R E, Rinder H M. Acquired von Willebrand's disease: a concise review.  Am J Hematol. 1997;  54 139-145
    PubMedGoogle Scholar
  • 28 Jakway J L. Acquired von Willebrand's disease.  Hematol Oncol Clin North Am. 1992;  6 1409-1419
    PubMedGoogle Scholar
  • 29 Delonca J, Balteaux V, Giraud T, Sanchez R Y. EDRF/NO and endothelial functions.  Arch Mal Coeur Vaiss. 1993;  86 1617-1624
    PubMedGoogle Scholar
  • 30 Hunley T E, Iwasaki S, Homma T, Kon V. Nitric oxide and endothelin in pathophysiological settings.  Pediatr Nephrol. 1995;  9 235-244
    CrossrefPubMedGoogle Scholar
  • 31 Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function.  Med Sci Monit. 2001;  7 1075-1085
    PubMedGoogle Scholar
  • 32 Naseem K M. The role of nitric oxide in cardiovascular diseases.  Mol Aspects Med. 2005;  26 33-65
    PubMedGoogle Scholar
  • 33 Rush J W, Denniss S G, Graham D A. Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity.  Can J Appl Physiol. 2005;  30 442-474
    PubMedGoogle Scholar
  • 34 Banfi C, Mussoni L, Tremoli E. PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms.  Minerva Endocrinol. 2002;  27 181-191
    PubMedGoogle Scholar
  • 35 De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity.  J Endocrinol Invest. 2002;  25 899-904
    PubMedGoogle Scholar
  • 36 Malenfant M. Diabetic retinopathy: pathogenesis, risk factors, clinical picture, classification.  Bull Soc Belge Ophtalmol. 1995;  256 11-23
    PubMedGoogle Scholar
  • 37 Hano T, Nishio I. Hypertension in the patients with impaired glucose tolerance.  Nippon Rinsho. 1996;  54 2687-2691
    PubMedGoogle Scholar
  • 38 Schneider D J, Nordt T K, Sobel B E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients.  Diabetes. 1993;  42 1-7
    PubMedGoogle Scholar
  • 39 Kohler H P. Insulin resistance syndrome: interaction with coagulation and fibrinolysis.  Swiss Med Wkly. 2002;  132 241-252
    PubMedGoogle Scholar
  • 40 Wirth A, Rothenfelde B. Metabolic syndrome.  Versicherungsmedizin. 1996;  48 193-199
    PubMedGoogle Scholar
  • 41 Dunn E J, Grant P J. Type 2 diabetes: an atherothrombotic syndrome.  Curr Mol Med. 2005;  5 323-332
    CrossrefPubMedGoogle Scholar
  • 42 Banga J D. Coagulation and fibrinolysis in diabetes.  Semin Vasc Med. 2002;  2 75-86
    PubMedGoogle Scholar
  • 43 Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance.  Int J Clin Pract Suppl. 2000;  113 14-22
    PubMedGoogle Scholar
  • 44 Ghosh K. Thrombohaemorrhagic balance in diabetes mellitus.  J Indian Med Assoc. 2002;  100 428-433
    PubMedGoogle Scholar
  • 45 Ferrannini E, Galvan A Q, Gastaldelli A et al.. Insulin: new roles for an ancient hormone.  Eur J Clin Invest. 1999;  29 842-852
    CrossrefPubMedGoogle Scholar
  • 46 Juhan-Vague I, Alessi M C, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.  Ann Med. 1996;  28 371-380
    PubMedGoogle Scholar
  • 47 Janka H U. Insulin resistance and cardiovascular complications.  Wien Klin Wochenschr. 1994;  106 758-762
    PubMedGoogle Scholar
  • 48 Blann A D, Lip G Y. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus.  Diabet Med. 1998;  15 634-642
    CrossrefPubMedGoogle Scholar
  • 49 Porta M, Molinatti P, La Selva M, Molinatti G M. Endothelium and its morphofunctional changes in the pathogenesis of diabetic microangiopathy.  Minerva Med. 1988;  79 915-929
    PubMedGoogle Scholar
  • 50 McMillan D E. The effect of diabetes on blood flow properties.  Diabetes. 1983;  32(Suppl 2) 56-63
    PubMedGoogle Scholar
  • 51 Carr M E. Diabetes mellitus: a hypercoagulable state.  J Diabetes Complications. 2001;  15 44-54
    CrossrefPubMedGoogle Scholar
  • 52 McDonagh P F, Hokama J Y. Microvascular perfusion and transport in the diabetic heart.  Microcirculation. 2000;  7 163-181
    CrossrefPubMedGoogle Scholar
  • 53 Sobol A B, Watala C. The role of platelets in diabetes-related vascular complications.  Diabetes Res Clin Pract. 2000;  50 1-16
    PubMedGoogle Scholar
  • 54 Varughese G I, Tomson J, Lip G Y. Type 2 diabetes mellitus: a cardiovascular perspective.  Int J Clin Pract. 2005;  59 798-816
    CrossrefPubMedGoogle Scholar
  • 55 Luscher T F, Oemar B S, Yang Z, Noll G. Molecular and cellular mechanisms of arteriosclerosis and restenosis: possibilities of gene therapy.  Z Kardiol. 1996;  85 495-508
    PubMedGoogle Scholar
  • 56 Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes.  Diab Vasc Dis Res. 2005;  2 16-23
    PubMedGoogle Scholar
  • 57 Arjomand H, Roukoz B, Surabhi S K, Cohen M. Platelets and antiplatelet therapy in patients with diabetes mellitus.  J Invasive Cardiol. 2003;  15 264-269
    PubMedGoogle Scholar
  • 58 Colwell J A, Nesto R W. The platelet in diabetes: focus on prevention of ischemic events.  Diabetes Care. 2003;  26 2181-2188
    CrossrefPubMedGoogle Scholar
  • 59 Kirpichnikov D, Sowers J R. Diabetes mellitus and diabetes-associated vascular disease.  Trends Endocrinol Metab. 2001;  12 225-230
    PubMedGoogle Scholar
  • 60 Savage P J. Treatment of diabetes mellitus to reduce its chronic cardiovascular complications.  Curr Opin Cardiol. 1998;  13 131-138
    PubMedGoogle Scholar
  • 61 McMillan D E. Deterioration of the microcirculation in diabetes.  Diabetes. 1975;  24 944-957
    CrossrefPubMedGoogle Scholar
  • 62 Kessler L, Wiesel M L, Attali P, Mossard J M, Cazenave J P, Pinget M. Von Willebrand factor in diabetic angiopathy.  Diabetes Metab. 1998;  24 327-336
    Google Scholar
  • 63 Porta M, La Selva M, Molinatti P A. von Willebrand factor and endothelial abnormalities in diabetic microangiopathy.  Diabetes Care. 1991;  14 167-172
    CrossrefPubMedGoogle Scholar
  • 64 Bell D S. Alcohol and the NIDDM patient.  Diabetes Care. 1996;  19 509-513
    CrossrefPubMedGoogle Scholar
  • 65 Lyons D. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease.  Int J Cardiol. 1997;  62(Suppl 2) S101-S109
    PubMedGoogle Scholar
  • 66 Simopoulos A P. Omega-3 fatty acids in health and disease and in growth and development.  Am J Clin Nutr. 1991;  54 438-463
    PubMedGoogle Scholar
  • 67 Gerster H. Prevention of platelet dysfunction by vitamin E in diabetic atherosclerosis.  Z Ernahrungswiss. 1993;  32 243-261
    PubMedGoogle Scholar
  • 68 Hirano T. Lipoprotein abnormalities in diabetic nephropathy.  Kidney Int Suppl. 1999;  71 S22-S24
    PubMedGoogle Scholar
  • 69 Lobo R A, Carmina E. The importance of diagnosing the polycystic ovary syndrome.  Ann Intern Med. 2000;  132 989-993
    PubMedGoogle Scholar
  • 70 Zdrojewicz Z, Sztuka-Pietkiewicz A, Zarzycki A, Karwacki J. Serotonin-structure, activity and clinical significance.  Postepy Hig Med Dosw. 1998;  52 637-654
    PubMedGoogle Scholar
  • 71 McCarty M F. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke - just say NO to stroke!.  Med Hypotheses. 2000;  55 386-403
    CrossrefPubMedGoogle Scholar
  • 72 Ferns G A, Motani A S, Anggard E E. The insulin-like growth factors: their putative role in atherogenesis.  Artery. 1991;  18 197-225
    PubMedGoogle Scholar
  • 73 Tschudi M R, Noll G, Luscher T P. Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors.  Schweiz Med Wochenschr. 1997;  127 636-649
    PubMedGoogle Scholar
  • 74 Mombouli J V. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide.  Drugs. 1997;  54(Suppl 5) 12-22
    PubMedGoogle Scholar
  • 75 Koppel H, Eber B, Gasser R, Klein W. Recent molecular and pharmacologic aspects of ACE inhibitors.  Wien Med Wochenschr. 1995;  145 633-637
    PubMedGoogle Scholar
  • 76 Ridker P M. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease.  Haemostasis. 1997;  27(Suppl 1) 2-11
    PubMedGoogle Scholar
  • 77 Klein M, Barbe F, Kaminsky P, Duc M. Disorders of hemostasis in dysthyroidism.  Pathol Biol (Paris). 1993;  41 268-275
    PubMedGoogle Scholar
  • 78 Ford H C, Carter J M. Haemostasis in hypothyroidism.  Postgrad Med J. 1990;  66 280-284
    CrossrefPubMedGoogle Scholar
  • 79 Squizzato A, Romualdi E, Buller H R, Gerdes V E. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review.  J Clin Endocrinol Metab. 2007;  92 2415-2420
    CrossrefPubMedGoogle Scholar
  • 80 Squizzato A, Gerdes V E, Ageno W, Buller H R. The coagulation system in endocrine disorders: A narrative review.  Intern Emerg Med. 2007;  2 76-83
    CrossrefPubMedGoogle Scholar
  • 81 Michiels J J, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine.  Clin Appl Thromb Hemost. 2001;  7 113-115
    CrossrefPubMedGoogle Scholar

Ashraf Mina 

Institute of Clinical Pathology and Medical Research (ICPMR)

Westmead Hospital, Westmead, N.S.W. 2145, Australia

Email: ashraf.mina@swahs.health.nsw.gov.au

      >